Claims for Patent: 8,097,238

Summary for Patent: 8,097,238

Title:	Cell targeting conjugates
Abstract:	The present invention relates to cell targeting conjugates and in particular, but not exclusively, to methods of their use in selectively eliminating and in selectively imaging target cells. The invention also relates to processes for production of the conjugates and to intermediate compounds that may be used in production of a specific class of cell targeting conjugates. In one embodiment there is provided a cell targeting conjugate comprising the following components that are covalently conjugated via a linker that is degradable within the target cells: i) a DNA minor groove binding ligand incorporating an effective Auger electron-emitting and/or gamma-emitting and/or positron-emitting atom or photoactive moiety; ii) a target cell specific protein or peptide that is capable of internalization by target cells.
Inventor(s):	Martin; Roger Francis (Ivanhoe, AU), White; Jonathan Michael (Wheelers Hill, AU), Lobachevsky; Pavel Nikolaevich (Bulleen, AU), Karagiannis; Thomas Chris (Thornbury, AU)
Assignee:	Peter MacCallum Cancer Institute (East Melbourne, AU)
Application Number:	10/590,784
Patent Claims:	1. A cell targeting conjugate comprising the following components that are covalently conjugated via a hydrazone, disulphide or amide bond linker that is degradable within the target cells: a DNA minor groove binding ligand incorporating an effective Auger electron-emitting, gamma-emitting or positron-emitting atom or photoactive moiety; a target cell specific protein or peptide that is capable of internalisation by target cells; wherein the cell targeting conjugate is represented by Formula (I), wherein: ##STR00025## X is carbon or nitrogen; Y.sub.1 and Y.sub.2 are selected from C(R'), nitrogen, N(R'), oxygen and sulfur, wherein R' is hydrogen, optionally substituted alkyl or optionally substituted alkenyl, and wherein Y.sub.1 and Y.sub.2 are not both either C(R') or nitrogen; .dbd. is a double bond unless the attached Y.sub.1 or Y.sub.2 is N(R'), oxygen or sulfur in which case it is a single bond; R.sub.1 to R.sub.12 are selected from hydrogen, halogen, hydroxy, amino, optionally substituted alkyl, optionally substituted alkenyl, a moiety including a target cell specific protein or peptide, an Auger electron-emitting moiety, a gamma-emitting moiety, a positron-emitting moiety and a photoactive moiety, and wherein two of R.sub.1 to R.sub.5 may together form optionally substituted cycloalkyl, cycloalkenyl or aryl; wherein at least one of R.sub.1 to R.sub.12 comprises a target cell specific protein or peptide, and wherein at least one other of R.sub.1 to R.sub.12 comprises an Auger electron-emitting moiety, a gamma-emitting moiety, a positron-emitting moiety and/or a photoactive moiety; and salts and/or tautomers thereof. 2. The cell targeting conjugate according to claim 1 wherein the target cell specific protein or peptide is selected from anti-A33, C595, 4D5, trastuzumab, egf/R3, humanized h-R3, C225, BrE-3, murine A7, C50, humanized MN-14, anti-A33, MSN-1, bivatuzumab, U36, KIS1, HuM195, anti-CD45, anti-CD19, TXU(anti-CD7)-pokeweed antiviral protein, M195, anti-CD23, apolizumab (Hu1D10), Campath-1H, N901, Ep2, somatostatin analogues, tositumomab, ibritumomab tiuxetan, HB22.7, anti-CD40, OC125, PAM4 and J591. 3. The cell targeting conjugate according to claim 1 wherein the gamma-emitting or positron-emitting moiety is distanced from a DNA minor groove binding region of the conjugate. 4. A cell targeting conjugate according to claim 3 selected from the following: ##STR00026## ##STR00027## wherein R represents hydrogen, hydroxy, amino, halogen or optionally substituted alkyl, alkenyl or alkynyl, and wherein the gamma-emitting or positron-emitting moiety is iodine (I).

Details for Patent 8,097,238

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-02-27
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-02-27
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2024-02-27
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2024-02-27